Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 5.94
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The company was founded in 1994 and is headquartered in Taipei, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Data is available to registered users only
